Foghorn Therapeutics (FHTX) Equity Average (2020 - 2025)
Historic Equity Average for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$83.2 million.
- Foghorn Therapeutics' Equity Average fell 29033.3% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.2 million, marking a year-over-year decrease of 29033.3%. This contributed to the annual value of -$61.4 million for FY2024, which is 5921.27% down from last year.
- As of Q3 2025, Foghorn Therapeutics' Equity Average stood at -$83.2 million, which was down 29033.3% from -$69.2 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Equity Average registered a high of $135.7 million during Q1 2021, and its lowest value of -$87.3 million during Q1 2024.
- Over the past 5 years, Foghorn Therapeutics' median Equity Average value was -$21.3 million (recorded in 2024), while the average stood at $2.5 million.
- Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 128256.37% in 2021, then tumbled by 65075.92% in 2023.
- Quarter analysis of 5 years shows Foghorn Therapeutics' Equity Average stood at $88.9 million in 2021, then plummeted by 86.26% to $12.2 million in 2022, then tumbled by 650.76% to -$67.3 million in 2023, then soared by 45.15% to -$36.9 million in 2024, then crashed by 125.32% to -$83.2 million in 2025.
- Its Equity Average stands at -$83.2 million for Q3 2025, versus -$69.2 million for Q2 2025 and -$53.6 million for Q1 2025.